Dmitriy Zamarin, MD, PhD

Assistant Attending Physician

Dmitriy Zamarin, MD, PhD

Assistant Attending Physician

Share
Print
Share
Print
Dmitriy Zamarin, MD, PhD

Office Phone

646-888-4882

Lab Phone

646-888-2585

Genetically-engineered oncolytic viruses are an emerging class of cancer therapeutics which have shown significant clinical promise in the recent years. My research focuses on exploration of oncolytic viruses for cancer immunotherapy.  Specifically, I am using engineered Newcastle Disease Virus (NDV) to study the mechanisms of anti-tumor immunity induced by viruses and to develop novel anti-cancer agents. My main area of interest is exploring different immunotherapeutic strategies that could circumvent the limitations of oncolytic viruses and make oncolytic virus-based therapy applicable to all cancer types.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Dmitriy Zamarin discloses the following relationships and financial interests:

  • Calidi Biotherapeutics
    Ownership / Equity Interests; Provision of Services (uncompensated)
  • Defined Health
    Provision of Services
  • Hookipa Biotech
    Provision of Services (uncompensated)
  • Merck & Co Inc.
    Intellectual Property Rights
  • OncLive
    Provision of Services
  • Projects In Knowledge
    Provision of Services
  • Takeda Pharmaceuticals
    Provision of Services
  • Western Oncolytics
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures